Prostate specific antigen for early detection of prostate cancer: Longitudinal study

BMJ (Online)

Volumn 339, Issue 7724, 2009, Pages 793-

  Holmström, Benny ^a,b   Johansson, Mattias ^b,c   Bergh, Anders ^b   Stenman, Ulf Håkan ^d   Hallmans, Göran ^b   Stattin, Pär ^b  

^a GÄVLE HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BONE METASTASIS; CANCER DIAGNOSIS; CANCER GRADING; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CASE CONTROL STUDY; CLINICAL EVALUATION; CONTROLLED STUDY; EARLY DIAGNOSIS; FOLLOW UP; GLEASON SCORE; HUMAN; IMMUNOASSAY; LONGITUDINAL STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SWEDEN; VALIDITY; WORLD HEALTH ORGANIZATION;

AGED; BONE NEOPLASMS; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; HUMANS; LONGITUDINAL STUDIES; LYMPHATIC METASTASIS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 70349637766     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b3537     Document Type: Article

References (32)

1. Ross KS, Carter HB, Pearson JD, Guess HA. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 2000;284:1399-1405
2. Yao SL, Lu-Yao G. Interval after prostate specific antigen testing and subsequent risk of incurable prostate cancer. JUrol 2001;166:861-865 (Pubitemid 32750967)
3. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues. CA Cancer J Clin 2008;58:161-179
4. Lieberman R. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer. Am J Ther 2004;11:501-506
5. Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, et al. Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol Suppl 2005;216:64-81. (Pubitemid 40979094)
6. Kwiatkowski M, Stieber P, Huber AR, Recker F. Selective application of tumor markers PSA. Ther Umsch 2008;65:493-501.
7. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl JMed 2009;360:1320-1328
8. De Koning HJ, Auvinen A, Berenguer Sanches A, Calais da Silva F, Ciatto S, Denis L, et al. Large-scale randomized prostate cancer screening trials: program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 2002;97:237-244 (Pubitemid 34019961)
9. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004;100:1397-1405 (Pubitemid 38366842)
10. Maattanen L, Hakama M, Tammela TL, Ruutu M, Ala-Opas M, Juusela H, et al. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial. Br J Cancer 2007;96:56-60. (Pubitemid 46094639)
11. Makinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, et al. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng/ml: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests. J Urol 2001;166:1339-1342 (Pubitemid 32862171)
12. Barry MJ. Prostate-specific-antigen testing for early diagnosis of prostate cancer.N Engl J Med 2001;344:1373-1377
13. Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ 2004;329:168-169
14. Jaeschke R, Guyatt G, Lijmer J. Diagnostic tests. In: Guyatt G, Rennie D, eds. Users' guides to the medical literature. Chicago: A MA Press, 2002:121-140
15. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005;294:66-70. (Pubitemid 41002840)
16. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994;344:1594-1598 (Pubitemid 24365358)
17. Parkes C, Wald NJ, Murphy P, George L, Watt HC, Kirby R, et al. Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. BMJ 1995;311:1340-1343
18. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-294
19. Hakama M, Stenman UH, Aromaa A, Leinonen J, Hakulinen T, Knekt P. Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland. J Urol 2001;166:2189-2191 (Pubitemid 33065254)
20. Gann PH, Ma J, Catalona WJ, Stampfer MJ. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J Urol 2002;167:2427-2434 (Pubitemid 34533139)
21. Lilja H, Ulmert D, Bjork T, Becker C, Serio AM, Nilsson JA, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007;25:431-436 (Pubitemid 350002992)
22. Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, Kaaks R. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 2004;22:3104-3112 (Pubitemid 41103723)
23. Weinehall L, Hallgren CG, Westman G, Janlert U, Wall S. Reduction of selection bias in primary prevention of cardiovascular disease through involvement of primary health care. Scand J Prim Health Care 1998;16:171-176 (Pubitemid 28459674)
24. Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andren O, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007;41:456-477
25. Vessella RL, Noteboom J, Lange PH. Evaluation of the Abbott IMx automated immunoassay of prostate-specific antigen. Clin Chem 1992;38:2044-2054
26. Aus G, Damber JE, Khatami A, Lilja H, Stranne J, Hugosson J. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med 2005;165:1857-1861 (Pubitemid 41352080)
27. Fagan TJ. Nomogram for Bayes theorem [letter]. N Engl J Med 1975;293:257.
28. Andriole GL, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-1319
29. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004;159:882-890 (Pubitemid 38657490)
30. Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med 2006;355:2615-2617 (Pubitemid 44969120)
31. Lilienfeld AM. Some limitations and problems of screening for cancer. Cancer 1974;33:1720-1724
32. Baker SG. The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer. J Natl Cancer Inst 2003;95:511-515